Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

ESMO Guidance for Reporting Oncology real-World evidence (GROW)
Luís Castelo-Branco, Anna Pellat, Diogo Martins-Branco, et al.
Annals of Oncology (2023) Vol. 34, Iss. 12, pp. 1097-1112
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

A guide to artificial intelligence for cancer researchers
Raquel Pérez-López, Narmin Ghaffari Laleh, Faisal Mahmood, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 427-441
Closed Access | Times Cited: 72
Artificial Intelligence in Oncology: Current Landscape, Challenges, and Future Directions
William Lotter, Michael J. Hassett, Nikolaus Schultz, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 711-726
Open Access | Times Cited: 36
Artificial intelligence in liver cancer — new tools for research and patient management
Julien Caldéraro, Laura Žigutytė, Daniel Truhn, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 8, pp. 585-599
Closed Access | Times Cited: 13
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development
C. Benedikt Westphalen, Diogo Martins-Branco, Juliana Rodrigues Beal, et al.
Annals of Oncology (2024) Vol. 35, Iss. 11, pp. 936-953
Open Access | Times Cited: 13
Privacy-preserving large language models for structured medical information retrieval
Isabella C. Wiest, Dyke Ferber, Jiefu Zhu, et al.
npj Digital Medicine (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 10
Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data
Danielle Delombaerde, Clara L. Oeste, Vincent Geldhof, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 7, pp. 100111-100111
Closed Access | Times Cited: 1
Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records
L. Mazzeo, F Corso, Paolo Baili, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 7, pp. 100109-100109
Closed Access | Times Cited: 1
Resistance to Immunotherapy in Non-small Cell Lung Cancer: Unraveling Causes, Developing Effective Strategies, and Exploring Potential Breakthroughs
Shuang Dong, Xiaoyu Li, Qing Huang, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101215-101215
Closed Access | Times Cited: 1
Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases
Thomas Grinda, Stefania Morganti, Liangge Hsu, et al.
npj Breast Cancer (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review
Nadia Harbeck, Adam Brufsky, Christopher M. Rose, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access | Times Cited: 1
From Text to Tables: A Local Privacy Preserving Large Language Model for Structured Information Retrieval from Medical Documents
Isabella C. Wiest, Dyke Ferber, Jiefu Zhu, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 21
Generating and using real-world data: A worthwhile uphill battle
Karin Verkerk, Emile E. Voest
Cell (2024) Vol. 187, Iss. 7, pp. 1636-1650
Open Access | Times Cited: 8
Large language model use in clinical oncology
Nicolas Carl, Franziska Schramm, Sarah Haggenmüller, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 8
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events
Najib Ben Khaled, Marie Møller, Leonie Jochheim, et al.
JHEP Reports (2024) Vol. 6, Iss. 6, pp. 101065-101065
Open Access | Times Cited: 7
Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC
Yuji Uehara, Yuki Takeyasu, Tsutomu Yoshida, et al.
ESMO Real World Data and Digital Oncology (2024) Vol. 5, pp. 100058-100058
Open Access | Times Cited: 6
Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC)
Ricky Frazer, John McGrane, Amarnath Challapalli, et al.
ESMO Real World Data and Digital Oncology (2024) Vol. 3, pp. 100027-100027
Closed Access | Times Cited: 6
Impact of neoadjuvant compared to adjuvant chemotherapy on prognosis in patients with hormone-receptor positive / HER2-negative breast cancer: A propensity score matching population-based study
Servah Hosseini-Mellner, Åsa Wickberg, Andreas Karakatsanis, et al.
The Breast (2024) Vol. 76, pp. 103741-103741
Open Access | Times Cited: 4
Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
Erik Olsson, Henrik Lindman, Evangelos Digkas, et al.
The Breast (2025) Vol. 79, pp. 103874-103874
Open Access
Real-world safety and effectiveness data of trastuzumab deruxtecan and sacituzumab govitecan in breast cancer: a Hellenic Cooperative Oncology Group study
Elena Fountzilas, Sofia Karageorgopoulou, Georgios Karakatsoulis, et al.
ESMO Real World Data and Digital Oncology (2025) Vol. 7, pp. 100095-100095
Closed Access
Prognostic impact of depth of response and early tumour shrinkage in patients with BRAFV600E-mutated metastatic colorectal cancer treated with targeted therapy
Guglielmo Vetere, Marco Maria Germani, Carlotta Antoniotti, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarcinoma in Spain
Rafael Álvarez-Gallego, Roberto Pazo-Cid, Borja Lopez De San Vicente, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Effectiveness, toxicity and impact on quality of life of high-dose-rate brachytherapy delivered in two fractions as monotherapy in patients with prostate cancer
Johan Staby Olsén, Antonios Valachis, Bengt Johansson
Clinical and Translational Radiation Oncology (2025) Vol. 51, pp. 100923-100923
Open Access
Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence
Matteo Loverro, C. Marchetti, Vanda Salutari, et al.
ESMO Open (2025) Vol. 10, Iss. 2, pp. 104119-104119
Closed Access
Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan
Alessandra Fabi, Alessandro Rossi, Roberta Caputo, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
The association between level IV/V metastasis and the recurrence, distant metastasis, and survival outcomes in hypopharyngeal squamous cell carcinoma
Ruichen Li, Qi Wang, Siyuan Ma, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Page 1 - Next Page

Scroll to top